Clean Yield Group Grows Position in Stryker Corporation $SYK

Key Points

• Clean Yield Group increased its holding in Stryker Corporation by 212.2%, owning a total of 14,361 shares worth approximately $5.68 million after acquiring additional shares in the second quarter.
• Stryker's recent earnings report showed an EPS of $3.13, surpassing estimates, and the company set a fiscal year 2025 guidance of 13.400-13.600 EPS.
• The company announced a quarterly dividend of $0.84, indicating a 0.9% dividend yield, to be paid to stockholders on October 31st.

Clean Yield Group raised its position in Stryker Corporation (NYSE:SYK - Free Report) by 212.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,361 shares of the medical technology company's stock after purchasing an additional 9,761 shares during the quarter. Stryker accounts for approximately 1.7% of Clean Yield Group's portfolio, making the stock its 18th largest holding. Clean Yield Group's holdings in Stryker were worth $5,682,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of SYK. Brighton Jones LLC raised its holdings in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after purchasing an additional 609 shares during the period. Moody National Bank Trust Division purchased a new position in shares of Stryker in the 1st quarter worth about $212,000. BTC Capital Management Inc. raised its holdings in shares of Stryker by 6.7% in the 1st quarter. BTC Capital Management Inc. now owns 2,741 shares of the medical technology company's stock worth $1,020,000 after purchasing an additional 171 shares during the period. Fifth Third Wealth Advisors LLC raised its holdings in shares of Stryker by 23.5% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 5,190 shares of the medical technology company's stock worth $1,932,000 after purchasing an additional 986 shares during the period. Finally, Abner Herrman & Brock LLC raised its holdings in shares of Stryker by 2.0% in the 1st quarter. Abner Herrman & Brock LLC now owns 32,514 shares of the medical technology company's stock worth $12,103,000 after purchasing an additional 634 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on SYK. BTIG Research reiterated a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Wall Street Zen lowered Stryker from a "buy" rating to a "hold" rating in a research note on Friday. Needham & Company LLC increased their target price on Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Evercore ISI increased their target price on Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Finally, Wells Fargo & Company increased their target price on Stryker from $435.00 to $445.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Fourteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $430.33.

Stryker Price Performance

SYK stock opened at $368.83 on Monday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The stock's 50 day moving average is $385.71 and its two-hundred day moving average is $379.18. The company has a market capitalization of $141.01 billion, a PE ratio of 48.85, a P/E/G ratio of 2.66 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. During the same period in the previous year, the business earned $2.81 EPS. Stryker's revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker's dividend payout ratio (DPR) is presently 44.50%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares of the company's stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.